Meesha Patel, 27 May 2026, Imperial College London RIO trial shows a new HIV treatment (broadly neutralising antibody therapy) enables three quarters of participants to safely control HIV without daily medication Summary A randomised placebo-controlled clinical trial led by Imperial College London has shown that an immune-based treatment called broadly neutralising antibodies (bNAbs) enabled 75% […]
Aidsmap interview with Professor John Frater at CROI Conference
Gus Cairns from Aidsmap reported from the CROI conference, Denver 22-25 February 2026 following results showing that half the participants from placebo arm of the RIO HIV cure trial have prolonged viral load remission when given broadly neutralising antibodies. https://www.aidsmap.com/news/mar-2026/half-participants-placebo-arm-hiv-cure-trial-have-prolonged-viral-load-remission-when […]
RIO Trial featured by Nature Medicine as one of the clinical trials shaping medicine in 2026
RIO Trial Featured by Nature Medicine as One of the Clinical Trials Shaping Medicine in 2026 We’re thrilled to announce that the RIO clinical trial has been selected by Nature Medicine as one of the “Eleven clinical trials that will shape medicine in 2026.” The feature highlights the most impactful and forward‑looking trials set to […]
RIO trial at the European AIDS Conference 2025, 15 – 18th October, Paris
At the conference, this Autumn this year, the RIO team spoke as part of a panel on the topic ‘Should we have ATI (analytical treatment interruption) trials and how?’. In this video, RIO participant Mr Marais talks about his experience on being part of the trial and provides a valuable insight on participating in an […]
First findings from RIO study shared by community representative on HIV i-Base
RIO is a randomised (1:1) placebo-controlled study looking at whether participants receiving two LS-bNABs (Arm A) could maintain viral load suppression off-ART during an analytic treatment interruption (ATI), for longer than participants who received a placebo (Arm B). Criteria to restart ART during the ATI included viral load >1000 copies/mL for six weeks or confirmed […]
Aidsmap writes about the RIO trial results at CROI 2025
In this article from Aidsmap, Gus Cairns writes on the RIO trial results presented by Professor Sarah Fidler at CROI conference on 10th March 2025. Chief investigator Professor Sarah Fidler of Imperial College London told the conference that 23.5% of bnAb recipients (eight people) had the typical viral rebound pattern of a rapidly increasing viral […]
Professor Sarah Fidler presents RIO Trial primary outcome at CROI – promising advances in HIV treatment
RIO Trial Demonstrates Long-Acting Immune-Based Therapy can achieve Sustained HIV Control We are delighted to report promising results of the primary outcome of our RIO Trial, which tested long-acting immune-based therapies for HIV. The study recruited 68 participants across 12 clinical sites in the UK and Denmark, who stopped their antiretroviral treatment and received either […]
Dr Ming Lee, RIO Trial Physician, appearance on the STI Podcast, IAS Conference Feedback 2023
After presenting at the 2023 HIV Cure & Immunotherapy Forum held alongside International AIDS Society (IAS) 2023, the 12th IAS Conference on HIV Science, in Brisbane, Dr Ming Lee was invited to appear on the Sexually Transmitted Infections (STI) Podcast. The episode, entitled IAS23 Conference Feedback in Brisbane, Australia in July 2023, discussed some of […]
Dr Ming Lee (RIO Trial physician) talk on bNAbs in clinical trials at IAS 2023, Brisbane.
Our RIO Clinical Research Fellow at Imperial College London and Imperial College Healthcare NHS Trust, Dr Ming Lee, was invited to speak at the 2023 HIV Cure & Immunotherapy Forum held alongside International AIDS Society (IAS) 2023, the 12th IAS Conference on HIV Science, in Brisbane, Australia. The talk included an overview of the RIO […]
Prof Sarah Fidler in Imperial College London podcast for Pride Month
13 June 2023 To celebrate Pride Month, Imperial College London has published a series of podcasts exploring stigma and the impact it has on mental health for people living with HIV. Our RIO Chief Investigator, Prof Sarah Fidler, discussed long-term treatment options with a view to improving the quality of life for people living with […]
